

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Airdoc Technology Co., Ltd.
北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2251)

INSIDE INFORMATION
CSRC APPROVAL FOR H SHARE FULL CIRCULATION

This announcement is made by Beijing Airdoc Technology Co., Ltd. (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

References are made to the circular dated October 25, 2022 and the announcement dated November 4, 2022 (the “**Announcement and Circular**”) in relation to, among others, the particulars of the Company’s application for “Full Circulation” of certain Unlisted Shares of the Company made to the China Securities Regulatory Commission (the “**CSRC**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement and Circular.

The Company is pleased to announce that the Company recently received the Reply of the Approval on the Overseas Listing of Domestic Unlisted Shares of Beijing Airdoc Technology Co., Ltd. (《關於核准北京鷹瞳科技發展股份有限公司境內未上市股份到境外上市的批覆》) (the “**Reply**”) from the CSRC, pursuant to which the CSRC approved 14 Shareholders of the Company to convert a total of 27,482,883 domestic Unlisted Shares held by them into overseas listed H Shares, which can be listed and traded on the Main Board of the Stock Exchange upon completion of the conversion (the “**Conversion and Listing**”). The Reply shall be valid for 12 months from the date of approval by the CSRC, namely March 20, 2023. Please refer to the Announcement and Circular for details of names of Shareholders and number of Unlisted Shares applied for full circulation. As of the date of this announcement, the details of the implementation plan of the H Share Full Circulation and the Conversion and Listing have not been finalized. The Company will

make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, March 28, 2023

As of the date of this announcement, the board of directors of the Company comprises Mr. ZHANG Dalei, Dr. CHEN Yuzhong and Mr. CHEN Hailong as executive directors; Mr. CHEN Xin as a non-executive director; and Mr. NG Kong Ping Albert, Mr. WU Yangfeng and Mr. HUANG Yanlin as independent non-executive directors.